

Stockholm 09/08/2021

Regarding trial 2007-006305-25: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome.

This trial ended prematurely as rimonabant due to adverse effects was taken off the market at the time the study started. One patient was included, but results are not available.

Charlotte Höybye, MD, PhD

Department of Endocrinology

Karolinska University Hospital

Stockholm, Sweden